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Background: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) has been identified as a putative cancer
stem cell (CSC) marker in breast cancer. However, the clinicopathological and prognostic significance of this protein
in breast cancer patients remains controversial.
Methods: This meta-analysis was conducted to address the above issues using 15 publications covering 921
ALDH1A1+ cases and 2353 controls. The overall and subcategory analyses were performed to detect the association
between ALDH1A1 expression and clinicopathological/prognostic parameters in breast cancer patients.
Results: The overall analysis showed that higher expression of ALDH1A1 is associated with larger tumor size, higher
histological grade, greater possibility of lymph node metastasis (LNM), higher level expression of epidermal growth
factor receptor 2 (HER2), and lower level expression of estrogen receptor (ER)/progesterone receptor (PR). The
prognosis of breast cancer patients with ALDH1A1+ tumors was poorer than that of the ALDH1A1− patients.
Although the relationships between ALDH1A1 expression and some clinicopathological parameters (tumor size,
LNM, and the expression of HER2) was not definitive to some degree when we performed a subcategory analysis,
the predictive values of ALDH1A1 expression for histological grade and survival of breast cancer patients were
significant regardless of the different cutoff values of ALDH1A1 expression, the different districts where the patients
were located, the different clinical stages of the patients, the difference in antibodies used in the studies, and the
surgery status.
Conclusions: Our results indicate that ALDH1A1 is a biomarker to predict tumor progression and poor survival of
breast cancer patients. This marker should be taken into consideration in the development of new diagnostic and
therapeutic program for breast cancer.
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Cancer stem cells (CSCs), although being a small percent-
age of the cancer cell population, are characterized by
their multipotency and the ability to initiate cancer and
propagate metastases [1-3]. Since the first report of these
cells, which were found among acute myeloid leukemia
cells by cell sorting technology using multiple surface
markers [4], CSCs have been reported in various tumors,
such as colon cancer [5], brain tumor [6], and lung cancer
[7]. Due to their high tumorigenic and metastatic poten-
tial, CSCs are thought to be the most formidable obstacle
to the successful treatment of cancer.
CSCs also have been isolated from breast cancer [8,9],
the most common malignancy in women worldwide. In
2003, Al-Hajj et al. have identified and isolated breast
CSCs from patients using the cell surface marker pattern
CD44+CD24-/lowLineage- [10]. Subsequently, Ginestier et al.
have reported that the activity of aldehyde dehydrogenase 1
(ALDH1) as assessed by the Aldefluor assay is a specific in-
dicator for identifying, isolating, and tracking human breast
CSCs [11].
The ALDH1A subfamily comprises three isoforms
(ALDH1A1, ALDH1A2, and ALDH1A3), which synthesize
retinoic acid (RA) from the retina and are crucial regula-
tors for the RA signaling pathway. These enzymes have a
high affinity for the oxidation of both all-trans- and 9-cis-
retinal and thereby serve to regulate the self-renewal and
differentiation of normal stem cells and CSCs [12].
Although the exact isoform of ALDH1A responsible for
the enzymatic activity assessed by BODIPY aminoacetal-
dehyde remains controversial [13-16], aldehyde dehydro-
genase 1 family member A1 (ALDH1A1) is thought to
have a predominant role [17]. Thus, much attention has
been focused on the relationship between the expression
of this isoform and the clinicopathologic parameters,
including prognosis, of breast cancer patients.
However, the prognostic value of ALDH1A1 for breast
cancer remains controversial despite numerous inde-
pendent studies. For example, in a series of 577 breast
carcinomas, Christophe Ginestier et al. demonstrated
that ALDH1A1 expression detected by immunostaining
correlated with poor patient prognosis [11]. Mieog et al.
have revealed that the prognostic value of ALDH1A1
expression is age dependent and can be observed only in
patients aged < 65 years [18]. Using a retrospective
collection of 321 node-negative and 318 node-positive
breast cancer patients with a mean follow-up time of
12.6 years, Neumeister et al. found that ALDH1A1
expression alone does not significantly predict thera-
peutic outcome [19]. Therefore, we performed a system-
atic review and a meta-analysis to assess the robustness
of the relationship between ALDH1A1 expression and
clinicopathologic parameters/outcomes in breast cancer
patients.Methods
Search strategy
We conducted a search of the PubMed and EMBASE
databases to identify studies for the systematic review.
Two major groups of studies were created according to
our objective. One group was used to clarify the associ-
ation between ALDH1A1 expression and clinicopatho-
logical parameters, including tumor size, lymph node
metastasis (LNM), histological grade, and the expression
of growth factor receptors (estrogen receptor, ER; pro-
gesterone receptor, PR; epidermal growth factor receptor
2, HER2). The other group was used to investigate the
association between ALDH1A1 expression and overall
survival (OS)/disease-free survival (DFS).
The search terms were “ALDH1”, “breast cancer”. All
studies were published prior to March 13, 2014. In the
initial retrieved literatures, we read the titles or abstracts
and screened for prognosis- and clinicopathology-related
research. Studies were included when the following cri-
teria were met: (1) published in English with the full text
available, (2) the use of a case control design or a cohort
design, and (3) the availability of data to allow the estima-
tion of the hazard ratio (HR) for survival with a 95% CI.
Accordingly, the exclusion criteria were as follows: (1)
reviews, abstracts and repeated studies; (2) ALDH1A1 not
specified as the subtype expressed; and (3) the use of
duplicate data. No ethnicity or regional restrictions were
applied. The review process was performed by two inde-
pendent reviewers.
Data extraction
The following information was extracted from these pa-
pers based the criteria listed above: first author, patients'
country, publication year, research technique used, num-
ber of cases and controls, cutoff value for ALDH1A1, anti-
body used, type of tumor samples, and HR. For references
that did not provide HRs, we referred to the methods
described by Tierney et al. [20] to obtain the HRs using
the data and figures from the original papers [19,21-23].
Statistical analysis
The prognosis of patients with breast cancer positive for
ALDH1A1 expression was calculated using the unadjusted
HR with the corresponding 95% CI according the OS/spe-
cific survival (SS)/relative survival (RS) and DFS/metasta-
sis-free survival (MFS)/recurrence-free survival (RFS) in
cases and controls. We classified different prognostic
parameters from included references, based on the char-
acteristics of censored data, into two groups: (1) OS/SS/
RS; (2) DFS/MFS/RFS. Other clinicopathological factors
were sorted into several subgroups: tumor size, LNM,
histological grade, and the expression of ER, PR, and
HER2. Fixed and random effects models were used to
calculate a pooled odds ratio (OR) and HR. The statistical
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the Z test and P values, and P < 0.05 was considered statis-
tically significant. Heterogeneity across studies was evalu-
ated by applying a Q test. In this approach, the Q value is
defined as identical to the effect size of the I2 value. A
random effects model was used when the I2 value for het-
erogeneity test was >50%; otherwise, a fixed effects model
was used. Begg’s rank correlation method and Egger’s
weighted regression method were used to assess publica-
tion bias (P < 0.05 was considered statistically significant).
All statistical tests for this meta-analysis were performed




A total of 16 studies from 15 publications [11,18,19,21-32]
were found to meet the criteria for this analysis after the
article titles, abstracts and main text were read to identify
case reports and clinical outcomes. The flow chart for the
identification of eligible studies is shown in Figure 1. The
total number of patients was 3274, including 921 cases
ALDH1A1+ breast cancer and a 2353 controls. Except in
the study by Neumeister, immunohistochemistry (IHC)
was a primary method used to evaluate ALDH1A1 expres-
sion in breast cancer specimens [19]. We identified the
detected subtype as ALDH1A1 based on the antibodies
listed in the references. For uniformed data analysis,
tumor size T1 was considered as low stage, and T2, T3,
and T4 as high stage. For the histological grade, all the
studies used Nottingham Combined Histology GradeFigure 1 Flow chart of eligible study identification.modified Scarff-Bloom-Richardson (SBR) grading system,
grades I and II were grouped together vs. grade III. In the
study by Ginestier et al., the patient samples were derived
from two independent groups (America and France) [11].
Therefore, these samples were divided into two studies:
the Ginestier U.M. set and the Ginestier I.P.C. set. The
prognostic data from Lee et al. [26] was not available,
because it was evaluated according to the change of ex-
pression of ALDH1A1 before and after the chemotherapy,
rather than the categories ALDH1A1+ and ALDH1A1−.
The main characteristics of the 16 eligible studies are
summarized in Table 1.
Meta-analysis results
Correlation of ALDH1A1 expression with clinicopathological
parameters
Overall analysis There were 14 references [11,18,21-32]
that assessed ALDH1A1 expression and correlated it to
tumor clinicopathological data. The overall analysis
showed significant association between ALDH1A1 ex-
pression and tumor size, histological grade, LNM, and
the expression of ER, PR, and HER2. Specifically, higher
ALDH1A1 expression means greater tumor size, higher
SBR grade, greater possibility of LNM, higher expression
of HER2, and lower expression of ER and PR. The re-
sults are shown in Figure 2 and Table 2.
Subcategory analysis Subsequently, we performed a sub-
category analysis according to different cutoff values of
ALDH1A1 expression (>5% and >0%/1% subgroups),
Table 1 Main characteristics of the eligible studies
Author Country Year Method
Cases Controls Cutoff of
Dilution of antibody Situation of patients HR
(ALDH1A1+) (ALDH1A1−) ALDH1A1 positive
Ginestier U.M. [11] America 2007 IHC (TMA) 24 122 > 5% BD Biosciences, 1:100 NA NA
Ginestier I.P.C [11] France 2007 IHC (TMA) 102 243 > 5% BD Biosciences, 1:100 NA 1.76
Morimoto [27] Japan 2009 IHC 21 182 > 0% BD Biosciences, 1:100 Treated with surgery 1.516
Charafe-Jauffret [24] France 2010 IHC 29 53 > 1% BD Biosciences, 1:50




Erika Resetkova [29] America 2010 IHC (TMA) 35 159 > 0% BD Biosciences, 1:200 Treated with surgery NA
Nalwoga [28] Uganda 2010 IHC (TMA) 88 95 unclear BD Biosciences, 1:250 NA NA
Neumeister [19] America 2010
Immunofluorescent
assays (AQUA)
45 581 NA BD Biosciences, 1:1000 Treated with surgery 2.32
Pei Yu [23] China 2010 IHC 18 78 > 0% Abcam, 1:100 Treated with surgery 4.6
He Lee [26] Korea 2011 IHC 12 80 >5% BD Biosciences, 1:100
Stage II ~ III, treated with
surgery
4.15
Yasuyo [31] Japan 2011 IHC 54 52 > 0% BD Biosciences, 1:1000 TNBC, treated with surgery 3.696
Yoshioka [32] Japan 2011 IHC 68 189 > 0% BD Biosciences, 1:1000 Treated with surgery
OS, 1.93
RFS, 1.667
Mieog [18] Netherlands 2012 IHC 292 195 > 0% BD Biosciences, NA Treated with surgery
RS, 2.36
RFS, 1.71
Nogami [21] Japan 2012 IHC 7 33 > 5% BD Biosciences, 1:200 ALNM+, treated with surgery 2.26




2013 IHC 35 106 >10% Abcam, 1:100 Treated with surgery NA
Dong [25] China 2013 IHC 56 105 >5% BD Biosciences, 1:200
Invasive ductal carcinoma and
ALNM+, treated with surgery
OS, 3.309
RFS, 2.774
a) IBC was defined as inflammatory breast cancer, it is stage IIIB.
b) TMA was defined as tissue microarrays.
c) AQUA was defined as automated quantitative analysis.
d) TNBC breast cancer was defined as triple-negative breast cancer.

















Figure 2 Meta-analysis of the association between ALDH1A1 expression and clinicopathological parameters: (A) LNM; (B) histological
grade; (C) tumor size; (D) the expression of ER; (E) the expression of PR; (F) the expression of HER2.
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Europe, Asia, and Africa subgroups), different clinical
stages of the patients [No assesment (NA) and ≥ stage II
subgroups], different antibodies used in the studies (BD
subgroup and Abcam subgroup), and types of surgery for
patients [Surgery, Part surgery, and No screened (NS)
subgroups].In the subgroup analysis based on the cutoff value, we
found that ALDH1A1 expression is positively correlated
with histological grade and negatively correlated with the
expression of ER/PR, which is consistent with the results
derived from overall analysis. At the same time, greater
tumor size and higher expression of HER2 in the
ALDH1A1 positive group could be found in the subgroup
Table 2 Main results of meta-analysis according to the different cutoff values of ALDH1A1expression
Parameter
Cutoff value Patients’ district Patients’ stage
5% 0% or 1% America-Europe Asia NA ≥Stage II
OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI
Tumor size 1.30 0.92-1.83 1.29* 1.01-1.65 1.24 0.95-1.61 1.37* 1.01-1.86 1.31* 1.06-1.62 1.19 0.66-2.14
LNM 1.43 0.99-2.07 1.20 0.94-1.54 1.33* 1.03-1.72 1.16 0.82-1.64 1.27* 1.03-1.56 1.29 0.33-4.97
SBR grade 2.33* 1.22-4.43 2.32* 1.20-4.49 2.16* 1.31-3.55 2.41* 1.16-5.04 2.37* 1.57-3.58 2.94 0.80-10.77
ER 0.46* 0.34-0.61 0.43* 0.33-0.55 0.47* 0.36-0.61 0.42* 0.32-0.54 0.41* 0.33-0.50 0.54* 0.36-0.82
PR 0.54* 0.30-0.98 0.46* 0.25-0.84 0.56* 0.33-0.96 0.45* 0.24-.0.84 0.43* 0.29-0.64 0.82 0.42-1.61
HER2 1.39 0.78-2.48 3.19* 1.67-6.08 2.39* 1.33-4.28 1.78 0.93-3.42 2.66* 1.76-4.03 0.89 0.54-1.48
OS/SS/RS 2.65* 1.82-3.86 2.33* 1.60-3.38 2.39* 1.83-3.13 3.10* 2.02-4.75 2.25* 1.71-2.95 3.51* 2.33-5.31
DFS/MFS/RFS 2.65* 1.54-4.57 2.04* 1.53-2.73 1.95* 1.33-2.85 2.36* 1.67-3.32 1.93* 1.41-2.65 2.68* 1.73-4.13
Parameter
Antibodies used in studies Surgery situation of patients
Overall
BD Abcam Surgery NS/Partly
OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI OR/HR 95% CI P I2
Tumor size 1.30* 1.06-1.60 1.05 0.38-2.93 - - - - 1.29* 1.06-1.58 0.012 0.0%
LNM 1.34* 1.08-1.67 0.76 0.39-1.48 - - - - 1.27* 1.03-1.56 0.024 0.0%
SBR grade 2.65* 1.73-4.08 1.27 0.63-2.56 - - - - 2.39* 1.61-3.54 0.000 70.4%
ER 0.43* 0.35-0.52 0.43* 0.36-0.52 - - - - 0.43* 0.36-0.52 0.000 42.3%
PR 0.54* 0.36-0.80 0.30* 0.15-0.57 - - - - 0.50* 0.35-0.71 0.000 65.1%
HER2 1.85* 1.19-2.87 2.83 0.53-15.07 - - - - 1.95* 1.29-2.95 0.002 65.5%
OS/SS/RS - - - - 2.87* 2.17-3.80 1.76* 1.06-2.91- 2.58* 2.05-3.23 0.000 38.0%
DFS/MFS/RFS 2.07* 1.60-2.69 4.60* 1.53-13.81 2.09* 1.60-2.75 2.72* 1.32-5.60 2.16* 1.68-2.79 0.000 0.0%
Ps. *means a significant difference.
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tus is not correlated with ALDH1A1 expression regardless
of cutoff value (Table 2 and Additional file 1: Figure S1).
Because there was only one study for African patients,
meta-analysis was performed for the America-Europe and
Asia subcategories according to different regions of the
patients. We found that the relationship between
ALDH1A1 expression and histological grade or the ex-
pression of ER/PR is the same as the results from previous
overall analysis, regardless of regions of origin. However,
tumor size in the America-Europe subgroup is not related
to ALDH1A1 expression. In addition, greater possibility of
LNM and higher expression of HER2 could be found in
America-Europe patients with high ALDH1A1 expression
in tumor (Table 2 and Additional file 2: Figure S2).
For subcategory analysis based on the clinical stage, six
clinicopathological parameters are all correlated with
ALDH1A1 expression in the NA group. However, in the
group ≥ stage II, ALDH1A1 expression is only correlated
with ER expression (Table 2 and Additional file 3: Figure S3).
For subcategory analysis based on the antibodies, six
clinicopathological parameters are also correlated with
ALDH1A1 expression in the BD group. In the Abcam
group, ALDH1A1 expression is only correlated with the
expression of ER and PR (Table 2 and Additional file 4:
Figure S4).Impact of ALDH1A1 expression on survival for breast cancer
There were a total of 11 references [11,18,19,21-25,
27,31,32] relating to the association between ALDH1A1 ex-
pression and breast cancer prognosis. The prognosis was
evaluated by the indicators OS/SS/RS and DFS/MFS/RFS.
The studies by Charafe-Jauffret [24], Yoshioka [32] and
Mieog [18] used two types of prognosis indicators, which
were classified by characteristics; OS/SS/RS made up one
group, DFS/MFS/RFS made up the other group.Overall analysis The data for this analysis indicated that
the prognosis of breast cancer patients with ALDH1A1+
was poorer than that of the ALDH1A1− patients regard-
less of the indicators used (OS/SS/RS or DFS/MFS/RFS).
The results were shown as follows: OS/SS/RS: OR = 2.58,
95% CI = 2.05–3.23, P = 0.000, I2 = 38.0%; DFS/MFS/RFS:
OR = 2.16, 95% CI = 1.68–2.79, P = 0.000, I2 = 0.0%
(Figure 3).Subcategory analysis ALDH1A1+ breast cancer patients
have poorer prognosis in all subcategory analysis. The re-
sults are shown in Table 2, Figure 3 and Additional file 5:
Figures S5, Additional file 6: Figure S6, Additional file 7:
Figure S7, Additional file 8: Figure S8 and Additional file
9: Figure S9.
Liu et al. BMC Cancer 2014, 14:444 Page 7 of 11
http://www.biomedcentral.com/1471-2407/14/444Sensitivity analysis Sensitivity analysis was performed
through the sequential omission of individual studies. The
corresponding pooled OR was not altered significantly for
any study factor after sequentially excluding each study,
demonstrating that our data are stable and reliable.
Publication bias
Begg’s funnel plot and Egger’s test were used to evaluate
the publication bias of all the relevant literature. The
statistical results did not show evidence of publication
bias: tumor size: Begg’s test, P = 0.755, Egger’s test, P =
0.721; LNM: Begg’s test, P = 0.640, Egger’s test, P = 0.342;
histological grade: Begg’s test, P = 0.583, Egger’s test, P =
0.766; expression of ER: Begg’s test, P = 0.511, Egger’s
test, P = 0.360; expression of PR: Begg’s test, P = 0.537,
Egger’s test, P = 0.278; expression of HER2: Begg’s test,
P = 0.855, Egger’s test, P = 0.749. Similar results were
found for OS/SS/RS: Begg’s test, P = 0.368, Egger’s test,
P = 0.155; DFS/MFS/RFS: Begg’s test, P = 0.266, Egger’s
test, P = 0.169. The funnel plot used to investigate the
relationship between ALDH1A1 expression and tumor
size is shown in Figure 4. The shape of the funnel plot
did not show obvious evidence of asymmetry.
Discussion
It is well known that ALDH1A1 can be used as a marker
for breast CSCs, which have high tumor-initiating and
self-renewal capabilities. Because of the important role
performed by breast CSCs in tumorigenesis, development,
and therapeutic outcomes, many groups have investigatedHeterogeneity between groups: p = 0.317























Figure 3 Meta-analysis of the association between ALDH1A1 expressithe relationship between the expression of ALDH1A1 and
the clinicopathologic features of breast cancer patients.
However, there are discrepancies among the studies
attempted to assess the association. Our results derived
from the meta-analysis of existing studies indicated that
ALDH1A1 can be used as a poor prognostic indicator in
breast cancer patients. The high expression of ALDH1A1
is positively associated with larger tumor size, higher
histological grade and a greater likelihood of LNM in
breast cancer patients. In addition, the expression of
ALDH1A1 was positively correlated with the expression
of HER2 but negatively correlated with the expression of
ER/PR. Moreover, if we performed subcategory analysis
based on the different cutoff values of ALDH1A1 expres-
sion, the different regions of origin of the patients, the dif-
ferent clinical stages of the patients selected, and the
different antibodies used in studies, the relationships be-
tween ALDH1A1 expression and some clinicopathological
parameters, including tumor size, LNM, and the expres-
sion of HER2, are slightly different. For example, the posi-
tive correlation between ALDH1A1 expression and the
tumor size only could be found in the cutoff >0/1%, Asia,
NA, and BD subgroups. Regarding LNM, a significantly
positive relationship with ALDH1A1 expression presented
in the America-Europe, NA, and BD subgroups. In
addition, the positive relationship between ALDH1A1 and
HER2 expression was observed in the cutoff >0/1%,
America-Europe, NA, and BD subgroups.
Only one eligible study from Yoshioka et al. indicated







































on and prognosis, including OS/SS/RS and DFS/MFS/RFS.











Figure 4 Begg’s funnel plot of publication bias. Each point represents a separate study for the indicated association (Tumor size).
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revealed that high expression of ALDH1A1 correlated
with larger tumor size, especially in the cutoff >0/1%, Asia,
NA, and BD subgroups. Multicenter prospective studies
based on large, homogeneous patient populations will be
required to assess the relationship between tumor size and
ALDH1A1 expression.
None of the studies eligible for the meta-analysis indi-
cated that ALDH1A1 expression was correlated with
LNM. However, our results from larger samples revealed
that there is a significant positive association between
these two parameters, especially in the America-Europe,
NA, and BD subgroups. This is supported by another
study by Neumeister et al. that was not included in our
meta-analysis due to the lack of some required informa-
tions. The study indicated that there is a significant associ-
ation between ALDH1A1 and LNM (OR = 2.37; 95%
CI = 1.582–3.165) [19]. In addition, a significant correlation
between ALDH1A1 expression in the primary tumor and
in the corresponding metastatic lymph nodes has been
observed. In a group of 48 breast cancer samples with
LNM, Yu et al. found that there were 8 ALDH1A1+ sam-
ples among the primary cancer tissues and 7 positive sam-
ples among the corresponding lymph node tissues. In
addition, there were 40 ALDH1A1− samples among the
primary cancer tissues, and 39 negative cases among
the corresponding lymph node tissues (P < 0.05) [23].
Similar results were also observed by Nogami [21].
These results suggest that ALDH1A1 might have an im-
portant role in LNM, and this relationship was mani-
fested in the results of our meta-analysis. However,
there was no significant correlation found between
ALDH1A1 expression and LNM in the Asia, ≥stage II,
and Abcam subgroups. This indicated that the previous
controversial conclusions about ALDH1A1 expression andLNM might result from the different races, clinical stages,
and antibodies used in studies; however, there are only 2
studies using the antibody from Abcam, which might re-
duce the power and accuracy of subcategory analysis. In
addition, there is no significant correlation between
ALDH1A1 expression and the 5 clinicopathological pa-
rameters (tumor size, LNM, SBR grade, PR, and HER2)
in the ≥ stage II subgroup. The small number of
included studies might also be the reason for this
situation. At the same time, it suggests that using the
expression level of a single molecule to assess the disease
development of advanced breast cancer patients might be
inadequate.
Based on the expression patterns of different molecular
markers, breast cancer can be divided into more than six
similar subgroups, which have distinguishing features with
respect to clinical outcomes, responses to adjuvant ther-
apy, and patterns of metastatic recurrence [33,34]. In
addition, a recent study suggested that there is a close rela-
tionship between the subtypes defined by gene expression
profiling and the cellular origin of breast cancer [35,36].
Thus, we also want to know the relationship between
ALDH1A1 expression and the three most important mo-
lecular markers of breast cancer, ER, PR, and HER2. The
results derived from overall analysis suggested that the
overexpression of ALDH1A1 might be related to the
enriched-HER2 subtype of breast cancer (ER−PR−HER2+),
which is derived from the transformation of mammary late
luminal progenitor cells [35,36]. However, it should be
noted that: First, the positive correlation between
ALDH1A1 expression and HER2 is only observed in the
America-Europe subgroup. Second, there were discrepan-
cies regarding the definition of HER2 positivity in the dif-
ferent studies. In some studies, tumors with scores of 2+
and 3+ were considered to be HER2 positive (more than
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staining) [11,23,27]. In other studies, only tumors with
scores of 3+ were considered HER2 positive (more than
30% of the cells showed positive immunohistochemical
staining) [21,22,26,32]. Only three studies confirmed the
amplification of HER2 by fluorescence in-situ hybridization
analysis [22,26,29]. Thus, other subtypes defined by gene
expression profiling, such as basal-like breast cancer with
moderate expression of HER2 (2 + ~3+), might have been
included in the HER2+ group in this meta-analysis.
ALDH1A1 expression might also be related to some basal-
like breast cancers, which are derived from the transform-
ation of mammary luminal progenitor cells [35,36]. The
results of Nalwoga et al. confirmed this possibility. They
found that there was a close relationship between
ALDH1A1 expression and the HER2 subtype (OR = 3.6,
95% CI = 1.4–9.7) and the basal-like subtype (OR = 4.0,
95% CI = 1.8–8.8) [28]. Similar results were found in the
study presented by Lee [26]. These data suggest that
ALDH1A1 could be used as a potential therapeutic target
for breast cancers of the HER2-enriched subtype or partial
basal-like subtype, especially in patients derived from
America-Europe.
It should be noted that there are some limitations to
this meta-analysis. First, although we endeavored to ex-
tract valid data from survival curves, in which HRs were
not directly measured, these indirect data are less reliable
than direct data from the original literature because these
calculated HRs are the result of univariate analyses and
might contain some deviations. Second, all of the studies
included in our meta-analyses are retrospective. Their ex-
perimental design may contribute to the heterogeneity,
which might reduce the analysis power to some extent.
Therefore, larger multicenter prospective studies based on
homogeneous populations are required to validate the
prognostic power of ALDH1A1. Third, publication bias is
a concern. We tried to identify all relevant data, but some
data were still missing. Some missing information, such as
the results presented by Marcato et al. [16], might reduce
the power of ALDH1A1 as a prognostic predictor in
breast cancer patients.Conclusion
This meta-analysis indicates that ALDH1A1 is an import-
ant predictor of the progression and poor survival of
breast cancer patients. Our results suggest that the ana-
lysis of ALDH1A1 expression in breast cancer not only
provides a better understanding of the relationship be-
tween breast tumorigenesis and cancer genomics but may
also be beneficial for the design of treatment and the as-
sessment of the prognosis of patients. We will further
study the influence of ALDH1A1 expression on differenti-
ation, invasion, and metastasis of breast cancer cells.Additional files
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ALDH1A1 expression and clinicopathological parameters according to
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the regions of origin of patients: (A) LNM; (B) histological grade; (C)
tumor size; (D) the expression of ER; (E) the expression of PR; (F) the
expression of HER2.
Additional file 3: Figure S3. Meta-analysis of the association between
ALDH1A1 expression and clinicopathological parameters according to
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